富勒烯及其衍生物在医药领域的应用研究进展
Application progress of fullerene and its derivatives in medicine
-
摘要: 富勒烯是一种有效的自由基清除剂和抗氧化剂,对富勒烯进行化学修饰得到的富勒烯衍生物具有良好的水溶性及生物活性。富勒烯及其衍生物具有抗氧化、细胞保护、抗微生物、光动力、载带药物和肿瘤治疗等多种活性,在医药领域发挥着重要作用,近几年这方面的研究又取得了较大进展。本文从调控肿瘤微环境、应用于药物载体和光动力疗法、抗氧化应激4个方面综述了富勒烯及其衍生物在医药领域的最新应用研究进展,并对其在医药领域的未来发展及应用进行展望。Abstract: Fullerene is an effective free radical scavenger and antioxidant. The fullerene derivatives obtained by chemical modification of fullerene have good water solubility and biological activities. Fullerene and its derivatives have many advantages in cell protection and antioxidant properties, antibacterial activity, antiviral activity, photodynamic activity, drug delivery and anti-tumor activities, playing an important role in the field of medicine. In recent years, great progress has been made in this field. In this review, we summarized the latest research progress and applications of fullerene and its derivatives in medicine field at home and abroad from four aspects of regulating tumor microenvironment, drug delivery, photodynamic therapy and anti-oxidative stress. At last, the future development and application of fullerene and its derivatives in the domain of medicine are prospected.
-
Keywords:
- fullerene /
- derivatives /
- medicine /
- applications
-
氟溴唑仑(flubromazolam,Flub)是通过改造阿普唑仑结构获得的一种新型苯二氮䓬类精神活性物质,其化学结构与阿普唑仑(alprazolam)类似,是在阿普唑仑结构8位添加了一个氟原子,并用溴取代了2′位氯原子。据报道,Flub具有快速且持久的中枢抑制作用,可使人体暂时性遗忘、昏迷、呼吸抑制[1]。2014年,德国首次发现Flub在人群中滥用[2]。2018年,中国也监测到Flub滥用[3]。2019–2021年,美国缉毒局(DEA)报告Flub滥用的案例逐年增加[4−6]。目前,关于Flub研究主要集中在定性定量分析及其代谢动力学等方面[7−10],其成瘾性及其机制尚不清楚。本研究拟建立小鼠条件性位置偏好(CPP)模型,以CPP评分评价Flub的奖赏效应,并检测腹侧被盖区(VTA)多巴胺(DA)能神经元以及喙内侧被盖核(RMTg)→VTA神经环路对Flub奖赏效应调控作用,为深入了解Flub成瘾性、开发安全有效的防治方法奠定基础。
1. 材 料
1.1 药品与试剂
氟溴唑仑(国家禁毒委员会办公室-中国药科大学禁毒关键技术联合实验室提供);羟丙基-β-环糊精,氟马西尼(flumazenil,FMZ)(上海源叶生物科技有限公司);氯氮平-N-氧化物(clozapine-n-oxide,CNO)(美国MCE公司);异氟烷(深圳瑞沃德生命科技有限公司);驴血清(江苏碧云天生物科技有限公司);酪氨酸羟化酶(tyrosine hydroxylase,TH)抗体(美国CST公司);c-Fos抗体(美国 Abcam公司);Alexa Fluor 594标记驴抗兔IgG,Alexa Fluor 488标记山羊抗小鼠IgG(上海翌圣生物科技有限公司);4',6-二脒基-2-苯基吲哚(4',6-diamidino-2-phenylindole,DAPI,北京索莱宝科技有限公司);其他试剂均为市售分析纯。
1.2 工具病毒信息
腺相关病毒包括AAV-TH-hM4Di-mCherry、AAV-GAD67-hM3Dq-mCherry、AAV-GAD67-hM4Di-mCherry、retro-AAV-GAD67-Cre-EGFP、retro-AAV-VGAT1-Cre、AAV-hSyn-DIO-hM3Dq-mCherry,均购自武汉枢密脑科学技术有限公司。AAV-TH-hM4Di-mCherry用于化学遗传调控VTA DA能神经元和相关环路;AAV-hSyn-DIO-hM3Dq-mCherry和retro-AAV-VGAT1-Cre用于化学遗传调控RMTg→VTA环路;AAV-GAD67-hM3Dq-mCherry用于顺向追踪RMTg脑区神经元的投射;retro-AAV-GAD67-Cre-EGFP用于VTA脑区神经元逆向追踪;AAV-GAD67-hM4Di-mCherry用于化学遗传调控RMTg→VTA环路。
1.3 仪 器
电子分析天平(德国Sartorius公司);倒置荧光显微镜,组织包埋机及石蜡切片机,CM1950冰冻切片机(德国Leica仪器有限公司);ANY-maze动物行为采集分析软件(美国Stoelting公司)。
1.4 动 物
C57BL/6J小鼠,SPF级,8周龄,体重20~25 g,由南京青龙山动物繁殖中心提供,合格证号:SCXK(浙)2019-0002。实验动物饲养于12 h昼夜交替的环境中,室温维持在(24±1)℃,湿度(55±5)%,动物可以自由饮水和摄食,实验开始前先适应性饲养1周。对动物的所有处理均遵循动物伦理委员会标准。
2. 方 法
2.1 小鼠CPP实验模型
实验装置由两个大小相同的正方体(24 cm×24 cm×30 cm)和一个长方体中间室(24 cm×10 cm×30 cm)构成,两个正方体的内壁颜色及底板触感不同,三室所连接隔板取出后小鼠可以在三室自由探索,实验开始时将小鼠从中间室放入,第1天和第2天将隔板取出,让小鼠在装置中自由探索15 min,第1天让小鼠熟悉实验环境,第2天进行前测,记录小鼠在初始偏好侧和初始非偏好侧(药物配对侧)的停留时间,第3~10天将隔板插入,第3,5,7,9天腹腔注射Flub后放入初始非偏好室训练40 min,第4,6,8,10天腹腔注射对照溶液后放入初始偏好室训练40 min。第11天进行测试,隔板取出后将小鼠从中间室放入,让小鼠在实验装置里探索15 min,记录小鼠在各室的停留时间,计算条件性位置偏好评分(CPP评分=测试时小鼠在药物配对侧停留时间–前测时小鼠在药物配对侧停留时间)。在化学遗传学实验中,将腺相关病毒注入目标脑区,病毒表达3~4周,在每次药物配对侧训练前30 min,腹腔注射CNO(2 mg/kg)或套管给予CNO(3 μmol/L,每侧200 nL)。氟马西尼(0.2 nmol/L,每侧200 nL)在每次药物配对侧训练前10 min套管注入RMTg脑区。
2.2 免疫荧光染色
用异氟烷气体吸入麻醉动物,分别用PBS和4%多聚甲醛心脏灌注,分离脑组织,用4%多聚甲醛固定48 h后,包埋、切片,石蜡切片厚度为8 μm,冰冻切片厚度为25 μm。石蜡组织切片在免疫荧光染色前进行抗原修复,脑片在4 ℃条件下孵育TH抗体(1∶500)、c-Fos抗体(1∶300)。4 ℃过夜后,PBS清洗切片3次,每次10 min,室温下避光孵育二抗2 h,用PBS清洗3次,每次10 min,随后孵育DAPI染色液(1∶100),10 min后PBS洗片3次,每次5 min。脑片干燥后滴加防猝灭剂封片,在荧光显微镜下观察。
2.3 脑立体定位注射
用异氟烷气体吸入麻醉动物,用宠物剃毛刀将小鼠头部毛发剔除,放置于定位框架上,碘伏消毒,随后用手术剪刀将小鼠头皮剪开大约1 cm小口,用颅骨钻在合适位置钻孔,脑立体定位注入工具病毒后用可吸收缝合线缝合。病毒注射位点为AP:–3.28 mm,ML:±0.5 mm,DV:–4.4 mm(VTA);AP:–4.04 mm,ML:±0.3 mm,DV:–4.3 mm(RMTg)注射病毒100 nL,表达3~4周后用于后续化学遗传学实验。
2.4 脑立体定位植入套管及经管给药
用异氟烷气体吸入麻醉动物,剔除小鼠头部毛发,放置于定位框架上,碘伏消毒,随后用手术剪刀将小鼠头皮剪开大约1 cm小口,用颅骨钻在目标区域上方钻孔,磨薄颅骨表面,拧上经酒精消毒的螺丝钉,将套管固定于套管夹持器上,待下落到目标区域后用牙科水泥固定,术后恢复1周再进行后续实验。通过注射内管将药物缓慢注入目标脑区,完成注射后将停针5 min,随后缓慢拔出注射内管,旋紧套管帽将小鼠放回笼中,待小鼠在笼内适应10 min后再进行药物配对训练。
2.5 数据分析
采用GraphPad Prism 9统计学软件对研究数据进行统计分析。计量资料以$ \bar{x} $±s表示,两组数据的比较用非配对t检验,两组以上数据组间比较采用单因素方差分析(One-Way ANOVA)检验或双因素方差分析(Two-Way ANOVA)检验。P<0.05表示差异具有统计学意义。
3. 结 果
3.1 Flub诱导小鼠CPP模型的建立
CPP 是一种巴甫洛夫条件反射形式,用于研究与滥用药物相关的奖赏效应。采用隔天训练的CPP范式,其实验流程见图1-A。剂量摸索实验发现,3 mg/kg Flub诱导小鼠CPP评分显著升高(P<0.05),而1、2和4 mg/kg Flub组小鼠CPP评分与对照组小鼠相比无显著性差异(图1-B)。
3.2 抑制VTA中多巴胺能神经元活性降低Flub诱导的CPP评分
VTA多巴胺能神经与药物引起的奖赏效应密切相关。采用免疫荧光检测VTA多巴胺能神经元c-Fos水平。结果显示,Flub诱导CPP小鼠VTA脑区c-Fos阳性细胞数较对照组显著增加(P<0.001)(图2-A ,B),而且c-Fos阳性神经元主要与TH阳性神经元共定位(P<0.01)(图2-A,C)。在VTA中注射携带多巴胺能神经元启动子的化学遗传抑制病毒AAV-TH-hM4Di-mCherry(图2-D,E),此病毒可在VTA DA能神经元上特异性表达带有红色荧光、经过改造的人M4毒蕈碱乙酰胆碱受体(hM4Di)。在药物配对侧训练前30 min腹腔注射CNO,通过hM4Di与特异性配体 CNO结合,特异性抑制VTA中多巴胺能神经元活性。行为学结果显示,化学遗传学抑制VTA中多巴胺能神经元,Flub诱导的小鼠CPP评分显著下降(P<0.05)(图2-F)。结果说明VTA多巴胺能神经元参与且调控Flub诱导的小鼠CPP。
Figure 2. Inhibition of ventral tegmental area (VTA) dopaminergic neuronal activity decreased Flub-induced CPP score A: Representative images showing c-Fos-positive cells and co-localization of c-Fos-positive neurons with tyrosine hydroxylase (TH); B: Statistical plot of number of c-Fos-positive neurons($ \mathit{\mathit{\bar{\mathrm{\mathit{x}}}\mathit{\mathit{\mathit{ }}}}} $±s,n=5); C: Statistical plot of co-localization of c-Fos-positive neurons with TH-positive neurons($ \bar{\mathrm{\mathit{x}}} $±s,n=5); D: Schematic diagram of virus injection; E:Expression of TH-hM4Di-mCherry (red) in the VTA; F: CPP score under chemogenetic inhibition of dopaminergic neurons in VTA of mice treated with Flub ($ \bar{\mathrm{\mathit{x}}} $±s,n=10)*P<0.05, **P<0.01, ***P<0.001,****P<0.00013.3 RMTgGABA→VTADA神经环路调控Flub诱导的小鼠CPP
由于VTA多巴胺能神经元接受VTA尾部RMTg的抑制性神经元投射,在RMTg注射携带GABA能神经元启动子的顺行红色荧光病毒AAV-GAD67-hM3Dq-mCherry(图3-A,B),此病毒可在RMTg GABA能神经元的胞体和轴突特异性表达红色荧光蛋白。病毒表达3周后显微镜观察显示,下游VTA脑区中可见由上游投射的大量红色输入细胞(图3-C)。在VTA注射逆行绿色荧光病毒retro-AAV-GAD67-Cre-EGFP(图3-D,E),此病毒可在上游GABA能神经元轴突和胞体中表达。病毒表达3周,显微镜观察可见RMTg脑区大量绿色病毒荧光(图3-F)。这些实验结果验证了RMTgGABA→VTADA神经环路的存在。
Figure 3. Suppression of rostrum tegmental nucleus (RMTg) inhibitory projections to VTA dopaminergic neurons is necessary for Flub-induced CPP A,D: Schematic diagram of virus injection; B: Expression of GAD67-mCherry (red) in the RMTg; C: mCherry-positive neuronal fibers from VTA-projecting RMTg γ-aminobutyric acid (GABA) neurons; E: Expression of EGFP(green) in the VTA; F:Expression of EGFP in the RMTg; G: Schematic diagram of virus injection; H: The expression of DIO-hM3Dq-mCherry (red) in the RMTg; I: CPP score in chemogenetic activation of RMTgGABA→VTA ($ \mathit{\bar{\mathrm{\mathit{x}}}\mathit{\mathit{\mathit{\mathit{ }}}}} $±s,n=10); J: Schematic diagram of virus injection; K: Representative diagram of cannula track in the VTA; L: CPP score in chemogenetic inhibitions of RMTgGABA→VTA and dopaminergic neurons in VTA($ \mathit{\bar{\mathrm{\mathit{x}}}\mathit{\mathit{\mathit{ }}}} $±s,n=12)**P<0.01为探究RMTgGABA→VTADA环路对Flub诱导的小鼠CPP是否有调控作用,在RMTg注射Cre依赖的红色荧光病毒AAV-hSyn-DIO-hM3Dq-mCherry,在VTA中注射retro-AAV-VGAT1-Cre病毒(图3-G,H),AAV-hSyn-DIO-hM3Dq-mCherry在 Cre 重组酶的作用下可在RMTg GABA 能神经元中特异性表达红色荧光蛋白和经改造的人M3 毒蕈碱受体(hM3Dq),通过给予特异性配体 CNO ,可启动下游 G蛋白信号通路,兴奋 GABA 能神经元。病毒表达3周后进行CPP实验,在药物配对侧训练前30 min腹腔给予CNO激活该环路。实验结果显示,激活环路RMTgGABA→VTADA后Flub诱导的小鼠CPP评分显著下降(P<0.01)(图3-I)。 此外,在RMTg注射AAV-GAD67-hM4Di-mCherry,在VTA注射AAV-TH-hM4Di-mCherry病毒,病毒表达3周后在VTA植入套管(图3-J),1周后进行CPP实验,在药物配对侧训练前30 min通过套管在VTA注射CNO(图3-K),通过hM4Di与特异性配体 CNO 结合,抑制该环路和VTA中多巴胺能神经元。实验结果显示,抑制RMTgGABA→VTADA环路和VTA多巴胺能神经元后Flub诱导的小鼠CPP评分与对照组相比,差异无统计学意义(图3-L)。这说明RMTgGABA→VTADA环路是通过VTA多巴胺能神经元调控Flub诱导的小鼠CPP。
3.4 Flub通过RMTg中的苯二氮䓬受体产生奖赏效应
为了探究Flub是否作用于RMTg脑区苯二氮䓬受体(亦称GABAA受体)产生奖赏效应,在RMTg植入套管(图4-A,B),1周后进行CPP实验,在药物配对侧训练前10 min通过套管在RMTg注入苯二氮䓬受体拮抗剂FMZ。实验结果显示,FMZ阻断RMTg中的苯二氮䓬受体显著降低Flub诱导的小鼠CPP评分(图4-C),这说明RMTg中的苯二氮䓬受体参与Flub诱导的奖赏效应。
Figure 4. Intra-RMTg infusion of flumazenil (FMZ) significantly reduced Flub-induced CPP score A: Schematic diagram of cannula track in the RMTg; B: Representative diagram of cannula track in the RMTg; C: CPP score in intra-RMTg of FMZ 10 min before administration of Flub (ip)($ \bar{\mathrm{\mathit{x}}} $±s,n= 9)**P<0.014. 讨 论
Flub属于未经批准上市的苯二氮䓬类新精神活性物质,其药理作用与阿普唑仑相似。本研究发现,Flub以3 mg/kg剂量腹腔注射4次小鼠CPP评分显著增加,而1 或2 mg/kg给药4次不能诱导小鼠CPP评分显著增加。Flub 4 mg/kg给药使小鼠出现反射减弱、镇静、呼吸抑制等中枢抑制作用,也不能诱导小鼠CPP评分显著增加。说明该药物的奖赏效应与剂量有关,这也从动物实验水平初步解释了Flub服用者描述在服药后感受到欣快感[11]。
精神活性物质所产生的欣快感在成瘾中起正性强化作用,VTA是药物奖赏的重要脑区,VTA多巴胺能神经元投射作用于伏隔核、杏仁核和前额叶皮层等多个脑区,形成中脑边缘奖赏系统,在成瘾药物诱导的奖励驱动行为过程中发挥重要作用[12]。化学遗传学抑制VTA中多巴胺能神经元可以降低Flub诱导的小鼠CPP评分,证实了VTA 多巴胺能神经元参与Flub诱导的奖赏效应。有研究表明苯二氮䓬类药物作用于GABAAα1亚基导致成瘾[13],因此,推测Flub可能通过与VTA上游脑区GABA能神经元GABAA受体结合,进而抑制GABA能神经元的活性,解除对VTA中多巴胺能神经元的抑制作用,从而使VTA多巴胺能神经元兴奋性增加,产生奖赏效应。RMTg是VTA多巴胺神经元抑制性GABA能输入的主要来源[14],越来越多研究表明,RMTg参与调节奖赏、动机、厌恶和行为回避[15−21]。Jalabert等[22]通过在RMTg注入顺行示踪剂或VTA注入逆行示踪剂来探究RMTg-VTA路的联系,发现在VTA中有顺行示踪剂,而在RMTg中检测到逆行示踪剂。本研究通过化学遗传学激活RMTgGABA→VTADA神经环路显著抑制Flub诱导的小鼠CPP,在RMTg经套管给予FMZ,阻断苯二氮䓬受体,也能够抑制Flub诱导的小鼠CPP。这提示Flub分布到RMTg 脑区,通过激动GABA能神经元GABAA受体,减少抑制性神经冲动至VTA多巴胺能神经元,使VTA多巴胺能神经元兴奋,产生奖赏效应。
综上所述,本研究采用评价药物精神依赖性的经典CPP动物模型,从分子、神经核团和神经环路水平揭示了Flub诱导奖赏效应的机制,为进一步研究Flub成瘾机制以及防治方法奠定了实验基础。
-
[1] Kroto HW,Weath JR,Curl RF,et al.C60:Buckminster fullerene[J].Nature,1985,318(6042):162-163. [2] Du GJ,Shi XY.New approaches to cancer treatment:targeting the tumor microenvironment[J].J Int Pharm Res(国际药学研究杂志),2011,38(5):336-340. [3] Nie X, Tang JL, Liu Y, et al. Fullerenol inhibits the cross-talk between bone marrow-derived mesenchymal stem cells and tumor cells by regulating MAPK signaling[J].Nanomedicine,2017,13(6):1879-1890. [4] Meng H,Xing GM,Blanco E,et al.Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition:imprisoning instead of poisoning cancer cells[J].Nanomedicine,2012,8(2):136-146. [5] Sun CD,Wang LM,Gao D,et al.C60(OH)22:a potential histone deacetylase inhibitor with anti-angiogenic activity[J].Nanoscale,2016,8(36):16332-16339. [6] Zhen MM,Shu CY,Li J,et al.A highly efficient and tumor vascular-targeting therapeutic technique with size-expansible gadofullerene nanocrystals[J].Sci China Mater(中国科学:材料科学),2015,58(10):799-810. [7] Zhou Y, Deng RJ, Zhen MM, et al. Amino acid functionalized gadofullerene nanoparticles with superior antitumor activity via destruction of tumor vasculature in vivo[J].Biomaterials,2017,133:107-118. [8] Chen ZY,Liu Y,Sun BY,et al.Polyhydroxylated metallofullerenols stimulate IL-1β secretion of macrophage through TLRs/MyD88/NF-κB pathway and NLRP3 inflammasome activation[J].Small,2014,10(12):2362-2372. [9] Tang JL,Chen ZY,Sun BY,et al.Polyhydroxylated fullerenols regulate macrophage for cancer adoptive immunotherapy and greatly inhibit the tumor metastasis[J].Nanomedicine,2016,12(4):945-954. [10] Lin MS,Chen RT,Yu NY,et al.Fullerene-based amino acid ester chlorides self-assembled as spherical nano-vesicles for drug delayed release[J].Colloids Surf B,2017,159:613-619. [11] Li Z,Zhang FL,Pan LL,et al.Preparation and characterization of injectable mitoxantrone poly(lactic acid)/fullerene implants for in vivo chemo-photodynamic therapy[J].J Photochem Photobiol B,2015,149:51-57. [12] Jovi'c DS,Seke MN,Djordjevic AN,et al.Fullerenol nanoparticles as a new delivery system for doxorubicin[J].RSC Advances,2016,6(45):38563-38578. [13] Raza K,Thotakura N,Kumar P,et al.C60-fullerenes for delivery of docetaxel to breast cancer cells:a promising approach for enhanced efficacy and better pharmacokinetic profile[J].Int J Pharm,2015,495(1):551-559. [14] Misra C,Thotakura N,Kumar R,et al.Improved cellular uptake,enhanced efficacy and promising pharmacokinetic profile of docetaxel employing glycine-tethered C60-fullerenes[J].Mater Sci Eng C,2017,76:501-508. [15] Thotakura N,Sharma G,Singh B,et al.Aspartic acid derivatized hydroxylated fullerenes as drug delivery vehicles for docetaxel:an explorative study[J].Artif Cells Nanomed Biotechnol,2017:1-10.doi: 10.1080/21691401.2017.1392314. [16] Wang L,Wang YT,Hao JC,et al.Magnetic fullerene-DNA/hyaluronic acid nanovehicles with magnetism/reduction dual-responsive triggered release[J].Biomacromolecules,2017,18(3):1029-1038. [17] Shi JJ,Yu XY,Wang L,et al.PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy,targeted drug delivery and MR imaging[J].Biomaterials,2013,34(37):9666-9677. [18] Shi JJ,Liu Y,Wang L,et al.A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer(fullerene)for in vitro and in vivo chemo-photodynamic therapy[J].Acta Biomaterialia,2014,10(3):1280-1291. [19] Lapin NA,Krzykawska-Serda M,Dilliard S,et al.The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60] fullerene derivative in a murine orthotopic model of breast adenocarcinoma[J].J Controlled Release,2017,260:92-99. [20] Shi JJ,Chen ZY,Wang L,et al.A tumor-specific cleavable nanosystem of PEG-modified C60@Au hybrid aggregates for radio frequency-controlled release,hyperthermia,photodynamic therapy and X-ray imaging[J].Acta Biomaterialia,2015,29:282-297. [21] Du B,Han SP,Li HY,et al.Multi-functional liposomes showing radiofrequency-triggered release and magnetic resonance imaging for tumor multi-mechanism therapy[J].Nanoscale,2015,7(12):5411-5426. [22] Shi JJ,Zhang HL,Wang L,et al.PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor[J].Biomaterials,2013,34(1):251-261. [23] Shi JJ,Wang BH,Wang L,et al.Fullerene(C60)-based tumor-targeting nanoparticles with“o, Bou?asset F, Gharbi N, et al. The prolongation of the lifespan of rats by repeated oral administration of [60] fullerene[J].Biomaterials,2012,33(19):4936-4946. [24] Cong WS,Wang P,Qu Y,et al.Evaluation of the influence of fullerenol on aging and stress resistance using caenorhabditis elegans[J].Biomaterials,2015,42:78-86. [25] Sun MR,Kiourti A,Wang H,et al.Enhanced microwave hyperthermia of cancer cells with fullerene[J].Mol Pharmaceutics,2016,13(7):2184-2192.lerene C60 penetration into leukemic cells and its photoinduced cytotoxic effects[J].Nanoscale Res Lett,2017,12(1):40. [26] Shi JJ,Wang L,Gao J,et al.A fullerene-based multi-functional nanoplatform for cancer theranostic applications[J].Biomaterials,2014,35(22):5771-5784. [27] Li Q,Hong L,Li HG,et al.Graphene oxide-fullerene C60(GO-C60)hybrid for photodynamic and photothermal therapy triggered by near-infrared light[J].Biosens Bioelectron,2017,89(Pt 1):477-482. [28] Guan MR,Ge JC,Li SM,et al.Multifunctional upconversion-nanoparticles-trismethylpyridylporphyrin-fullerene nanocomposite:a near-infrared light-triggered theranostic platform for imaging-guided photodynamic therapy[J].NPG Asia Mater,2015,7(7):e205. [29] Guan MR,Ge JC,Wu JY,et al.Fullerene/photosensitizer nanovesicles as highly efficient and clearable phototheranostics with enhanced tumor accumulation for cancer therapy[J].Biomaterials,2016,103:75-85. [30] Yin R,Wang M,Huang YY,et al.Antimicrobial photodynamic inactivation with decacationic functionalized fullerenes:oxygen-independent photokilling in presence of azide and new mechanistic insights[J].Free Radical Biol Med,2015,79:14-27. [31] Zhang YS,Dai TH,Wang M,et al.Potentiation of antimicrobial photodynamic inactivation mediated by a cationic fullerene by added iodide:in vitro and in vivo studies[J].Nanomedicine(Lond),2015,10(4):603-614. [32] Grinholc M,Nakonieczna J,Fila G,et al.Antimicrobial photodynamic therapy with fulleropyrrolidine:photoinactivation mechanism of staphylococcus aureus,in vitro and in vivo studies[J].Appl Microbiol Biotechnol,2015,99(9):4031-4043. [33] Ballatore MB,Durantini J,Gsponer NS,et al.Photodynamic inactivation of bacteria using novel electrogenerated porphyrin-fullerene C60 polymeric films[J].Environ Sci Technol,2015,49(12):7456-7463. [34] Zhou Y,Li J,Ma HJ,et al.Biocompatible [60] /[70] fullerenols:potent defense against oxidative injury induced by reduplicative chemotherapy[J].ACS Appl Mater Interfaces,2017,9(41):35539-35547. [35] Krokosz A,Grebowski J,Rodacka A,et al.The effect of fullerenol C60(OH)~30 on the alcohol dehydrogenase activity irradiated with X-rays[J].Radiat Phys Chem,2014,97:102-106. [36] Awan F,Bulger E,Berry RM,et al.Enhanced radical scavenging activity of polyhydroxylated C60 functionalized cellulose nanocrystals[J].Cellulose,2016,23(6):3589-3599. [37] Goodarzi S,Ros TD,Conde J,et al.Fullerene:biomedical engineers get to revisit an old friend[J].Mater Today,2017,20(8):460-480. [38] Dellinger A,Zhou ZG,Connor J,et al.Application of fullerenes in nanomedicine:an update[J].Nanomedicine,2013,8(7):1191-1208. [39] Huang J,Zhou C,He J,et al.Protective effect of reduced glutathione C60 derivative against hydrogen peroxide-induced apoptosis in HEK 293T cells[J].J Huazhong Univ Sci Technol(华中科技大学学报),2016,36(3):356-363. [40] Prylutskyy YI,Vereshchaka IV,Maznychenko AV,et al.C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue[J].J Nanobiotechnol,2017,15(1):8. [41] Baati T, Bourasset F, Gharbi N, et al. The prolongation of the lifespan of rats by repeated oral administration of [60] fullerene[J].Biomaterials,2012,33(19):4936-4946. [42] Cong WS,Wang P,Qu Y,et al.Evaluation of the influence of fullerenol on aging and stress resistance using caenorhabditis elegans[J].Biomaterials,2015,42:78-86. [43] Sun MR,Kiourti A,Wang H,et al.Enhanced microwave hyperthermia of cancer cells with fullerene[J].Mol Pharmaceutics,2016,13(7):2184-2192.
计量
- 文章访问数: 1873
- HTML全文浏览量: 11
- PDF下载量: 11120